Mauna Kea Technologies


Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the NYSE Euronext exchange.

Cellvizio Technology

Cellvizio technology generates cellular images using a small flexible microscope, providing clinicians with microscopic images of tissue in a minimally-invasive manner. A real-time image processing software combined with a high-speed Laser Scanning Unit allows Cellvizio to produce images at 12 frames per second.
Confocal Imaging Cellvizio belongs to a specific category of microscopes, called confocal laser microscopes.

Timeline

Recent Discoveries

Cellvizio probe-based confocal laser endomicroscopy technology or pCLE was instrumental in discovering the interstitium, a contiguous fluid-filled space existing between a structural barrier, such as a cell wall or the skin, and internal structures, such as organs, including muscles and the circulatory system. It is located in the submucosa that drains fluid into lymph nodes and is supported by collagen bundles. Researchers believe that this organ could be important in a number of pathological conditions including cancer metastasis, tissue edema and fibrosis, and has the potential of being the largest organ in the human body. Findings from the study co-led by an NYU Langone Health and Mount Sinai Beth were published in the March 27, 2018 issue of the peer-reviewed journal Scientific Reports